Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "real world," wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Real world data supporting identification of the pharmacist’s role in obesity and overweight treatment in Poland – a preliminary report
Autorzy:
Drozd, Mariola
Bułaś, Lucyna
Szkultecka-Dębek, Monika
Skowron, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/454892.pdf
Data publikacji:
2017
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
overweight
obesity
pharmaceutical care
treatment, real world data
Opis:
Introduction. Obesity is a significant health and economic problem, both for the patient and the health care system. An essential element in the prevention and treatment of each disease is the engagement of all groups of healthcare professionals. In our study, we performed an analysis of the real world data, obtained from a survey of the medical and socioeconomic problems associated with overweight and obesity. We aimed to identify the pharmacist’s role in the management of overweight and obese patients, including their individualized education in an outpatient setting. Material and methods. The study material consisted of responses obtained from a specially designed questionnaire. Our findings indicate that the study patients had easy access to a pharmacist’s professional knowledge, relevant to comprehensive treatment of obesity. In addition, our data indicates a lack of patient knowledge of a healthy lifestyle and an inability to implement such knowledge in practice. Results. The community pharmacist should actively provide support to patients with obesity (including the primary obesity and those who want to lose excessive body mass for health-related and also for aesthetic reasons) and the management of their weight. The results of our study should be considered as an introduction to further research to facilitate the understanding of problems and expectations of patients and to prepare pharmacists to perform pharmaceutical care (PC) in this regard. Conclusion. One of the potential options to protect society against the obesity epidemic is an education about the risks inherent to obesity and promotion of a healthy lifestyle.
Źródło:
European Journal of Clinical and Experimental Medicine; 2017, 3; 192-199
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Survival outcome and prognostic factors in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate – real-world experience in Vietnam
Autorzy:
Do, Tu Anh
Nguyen, Thai Hoa Thi
Nguyen, Hau Xuan
Nguyen, Loi Dinh
Nguyen, Chu Van
Powiązania:
https://bibliotekanauki.pl/articles/40555372.pdf
Data publikacji:
2024-06-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
abiraterone acetate
metastatic castration-resistant prostate cancer
overall survival
real-world evidence
Opis:
Introduction and aim. In real life, metastatic castration-resistant prostate cancer patients (mCRPC) had more complex clinical presentation than patients in the COU-AA-302 trial. This study primarily aimed to describe the overall survival of chemotherapy-naive mCRPC treated with abiraterone acetate plus prednisone (AAP). Other relevant outcomes and baseline characteristics of these patients were also evaluated. Material and methods. This retrospective, observational study collected data from chemotherapy-naive mCRPC patients treated with AAP in Vietnam. Kaplan-Meier curves were used to estimate time to treatment failure (TTF), and overall survival (OS). The impact of baseline characteristics on OS was explored using univariate and multivariate Cox proportional hazard models. Results. Data from 65 eligible patients were analyzed. The rate of PSA response was 73.8%, median PSA PFS was 10.5 months (95% CI: 7.4–13.6), median TTF was 15 months (95% CI: 11.1–18.9), and median OS was 24.9 months (95% CI: 18.9–30.9). Shorter OS was significantly associated with a higher Gleason score (≥8), shorter time from ADT start to mCRPC (<12 months), visceral metastases, and <50% PSA decline (p<0.05). Conclusion. Abiraterone acetate plus prednisone is well tolerated and effective for chemotherapy-naive mCRPC patients in clinical practice. Moreover, Gleason score, visceral metastasis, time from ADT start to mCRPC, and PSA response are the independent indicators for predicting the OS of mCRPC patients in both univariate and multivariate analyses.
Źródło:
European Journal of Clinical and Experimental Medicine; 2024, 22, 2; 262-269
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies